Results 91 to 100 of about 92,044 (339)
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun +23 more
wiley +1 more source
Integrated omics analysis of matched primary and liver metastatic NPC tumors reveals a unique NOTCH1+ CSC subpopulation exhibiting enhanced stemness properties and tumorigenic capacity. With in vitro and in vivo assays, exosomal transfer of tumor‐derived FTO from NOTCH1+ cells to the endothelium promotes vascular permeability and metastatic potential ...
Chun Wu +23 more
wiley +1 more source
Immune Predictors of Radiotherapy Outcomes in Cervical Cancer
This study reveals dynamic immune remodeling in cervical cancer following radiotherapy. Single‐cell analysis identifies the C3/C3AR1 axis as a central mediator of epithelial–myeloid crosstalk, whose inhibition reduces treatment efficacy in mice. Guided by these insights, the eight‐feature machine‐learning model: Cervical Cancer Radiotherapy Immune ...
Linghao Wang +8 more
wiley +1 more source
This study shows that lower NAM levels in PE‐derived pEVs correlate with disease severity. NAM‐deficient pEVs reduce Th1 and Th17 inhibition, leading to PE‐like symptoms. NAM in pEVs inhibits Th1 via SIRT1 and Th17 via macrophages. Reduced NAM in PE‐EVs is due to decreased HRS expression in trophoblasts, resulting from elevated HSP27.
Haiyi Fei +10 more
wiley +1 more source
Recommendations for clinical and molecular identification of LS, surgical and endoscopic management of LS‐associated colorectal cancer and preventive measures for cancer were produced. The emphasis was on surgical and gastroenterological aspects of the cancer spectrum.
T. T. Seppälä +18 more
wiley +1 more source
Metformin as a Therapeutic Target in Endometrial Cancers. [PDF]
Endometrial cancer is the most common gynecologic malignancy in developed countries. Its increasing incidence is thought to be related in part to the rise of metabolic syndrome, which has been shown to be a risk factor for the development of ...
Johnson, Jennifer +6 more
core +2 more sources
Mutant p53 drives oncogenic splicing to promote the progression of ovarian cancer by partnering with the spliceosome factor SNRPD2. Therefore, it is engineered iRGD‐exosomes to co‐deliver siRNAs against both targets. This approach restored tumor‐suppressive mRNA isoforms, effectively enhanced sensitivity to cisplatin, and ultimately blocked tumor ...
Wei Zhao +14 more
wiley +1 more source
Clean Cut is a multimodal, adaptive, checklist‐based infection prevention programme designed to improve compliance with six critical perioperative infection prevention practices. After introducing the programme at five hospitals in Ethiopia, compliance with critical infection prevention standards significantly improved and the relative risk of ...
J. A. Forrester +16 more
wiley +1 more source
The glycosyltransferase GALNT10 facilitates ovarian cancer metastasis through the induction of tumor cell EMT and tumor vascular dysfunction. GALNT10 enhanced the extracellular secretion of IGFBP7 through O‐GalNAc glycosylation modification at the T188 site, which subsequently interacts with CD93 on endothelial cells, leading to vascular remodeling ...
Yanan Zhang +9 more
wiley +1 more source
Christina H Son,1 Gini F Fleming,2 John W Moroney3 1Department of Radiation & Cellular Oncology, University of Chicago Medicine, 2Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, 3Section of Gynecologic Oncology,
Son CH, Fleming GF, Moroney JW
doaj

